Journal of psychopharmacology (Oxford, England)
January 30, 2026
Veronica Magar, Marlena Robbins, Óscar Martín López Fernández Lobo Blanco et al.
1 citation
Indigenous Peoples have cultivated and protected natural psychoactive medicines through ceremony, kinship, and spiritual responsibility across generations, yet their long-standing contributions have often been marginalized through extractive research, commercialization, and policy exclusion. It is Indigenous communities that have stewarded and gained expertise working with psychoactive...
International Journal of Innovative Technologies in Social Science
January 28, 2026
Łukasz Deska, Cezary Kosmecki, Dawid Głaz et al.
This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to synthesize current understanding regarding its mechanisms, efficacy, safety, costs, and accessibility, comparing it with conventional antidepressant and ketamine treatments. The methodology involved a narrative synthesis of academic literature, drawing...
Synthese
January 26, 2026
Celia R. Blaise
Abstract A recurring finding in psychedelic-assisted therapy is that the subjective intensity and quality of the psychedelic experience contribute more to therapeutic outcomes than the administered dose. To explain why such experiences are therapeutic, many have appealed to what these may reveal or enable, such as the types of mental representations that can be acquired, the expansion of what...
Cureus
January 25, 2026
Hana Abbasian
Psychedelic-assisted psychotherapy is gaining recognition as a novel approach in mental health care, with the potential to support emotional processing, self-understanding, and personal growth. Early evidence suggests that psychedelic-assisted therapies can catalyze transformative experiences that traditional interventions may not access. This article explores the ethical considerations of...
Frontiers in Psychiatry
January 22, 2026
Alka Christnacht, Therry Rose J Eparwa, Emily Whinkin et al.
The postpartum period is notorious for rapid and profound changes for birthing individuals and their families. Significant shifts to hormonal and physical health, routines and family roles, and the salience of personal and community risk factors all contribute to potential psychiatric and psychological distress for parents, sometimes diagnosed as a postpartum mood or anxiety disorder (PMAD)....
Journal of Clinical Psychopharmacology
January 12, 2026
Natia Horato, Felipe Dalvi-Garcia, Pablo E P Dutra et al.
1 citation
Treatment-resistant depression (TRD), a clinical subtype of major depressive disorder (MDD), is associated with greater severity and functional impairment, representing a significant challenge in psychiatric care. Recent studies suggest that the use of psychedelics can provide rapid and substantial improvement in the severity of depressive symptoms. Therefore, the aim of this systematic review...
Psychedelics
January 8, 2026
Rachel Yehuda, Amy Lehrner, Miryam Sperka et al.
2 citations
The original MAPS manual for MDMA-assisted therapy (MDMA-AT) opened a therapeutic frontier for PTSD. However, it drew critique for concepts—such as “inner healing intelligence” – that originated in transpersonal traditions rather than academic or empirically grounded clinical models. While many patients found the therapies helpful, these constructs were difficult to interpret and standardize....
JAMA Network Open
January 2, 2026
Gianluca Andri Florineth, Isabell Klima, Anna Laura Boeker et al.
5 citations
Psychedelic-assisted therapy (PAT) is a novel intervention for depressive symptoms, typically delivered with additional psychological therapy sessions. Quantitative evidence on how this concomitant therapy contributes to treatment outcomes is limited, highlighting the need for a systematic synthesis. To evaluate whether the quantity of psychological therapy is associated with symptom reduction...
Drug Design, Development and Therapy
2026
Fan Bu, Lan Qin, Zhengchi Lou et al.
Depressive disorders remain a major source of disability worldwide, and many patients do not achieve sustained remission despite the availability of multiple antidepressant options. Unmet needs are particularly evident in treatment-resistant depression (TRD) and bipolar depression, where delayed onset of action, incomplete response, relapse, residual functional impairment, and tolerability...
Issues in Mental Health Nursing
2026
Jennifer Tustison, Charlene Niemi, Kristen R. Choi
1 citation
The integration of psychedelic substances into mental health treatments represents one of the most significant paradigm shifts in psychiatric care in recent decades. This article examines the ethic...
The International journal on drug policy
2026
Guy Simon, Nir Tadmor, Demian Halperin
2 citations
Psychedelics induce transformative experiences leading to lasting changes in attitudes and behaviour, with outcomes depending on both pharmacological factors and the context of the experience ('set and setting'), marking a paradigm shift in mental health treatment. As psychedelics transition from traditional contexts to clinical settings, tension emerges between authenticity and...
Substance use & addiction journal
2026
Olivia Marcus, Brian Rush
There is an increasing interest in the use of psychedelics for the treatment of substance use disorders (SUDs) and to improve overall health and wellbeing. We aimed to update and complement research syntheses that have focused only on results from clinical trials by synthesizing the research across diverse methods to discuss implications from a broad and multi-faceted literature. We conducted a...
PLoS One
2026
Diego Castellano-Ramírez, Elisa Hernández-Álvarez, Lucas F Borkel et al.
Psychedelic-assisted therapy is regaining attention as a promising approach to treating mental health disorders. This research aimed to compare related factors regarding the therapeutic use of psychedelics between medical and nursing students, addressing a notable gap in existing research. A cross-sectional survey was conducted at the University of Las Palmas de Gran Canaria (Spain) during the...
Case Reports in Psychiatry
2026
Ridhi J. Vyas, Ryan Hood, Jeremy Hsiang et al.
3,4‐Methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy (MDMA‐AP) has shown promise in treating post‐traumatic stress disorder (PTSD), particularly in treatment‐resistant cases. However, little is known about its potential to precipitate adverse psychiatric outcomes. We present the case of a 31‐year‐old woman with nondistressing childhood compulsions, chronic PTSD, and complex medical...
Psychedelic Harm Reduction
2026
Ido Hartogsohn
13 citations
Set and setting is a fundamental concept in the field of psychedelic studies, denoting the crucial importance of context to determining the character and quality of experiences with psychedelics. This paper suggests a framework for thinking of set and setting and its relevance for psychedelic harm reduction. It discusses how “set,” the diverse factors related to an individual’s mindset, and...
Psychedelic Harm Reduction
2026
Michael Koslowski, Peter Gasser
6 citations
Psychedelic substances have gained recognition for their therapeutic potential, but they also present challenges, with individuals occasionally experiencing distressing episodes referred to as challenging experiences or, in the recreational setting, “bad trips”. Trial therapists and physicians, but also healthcare professionals in emergency rooms, need a comprehensive strategy to effectively...
Therapeutic Advances in Psychopharmacology
2026
Kristian Beichmann, Polina Catzeflis, Helena Aicher et al.
The Swiss Federal Office of Public Health provides case-by-case exemptions allowing physicians to provide psychedelic-assisted therapy (PAT) using psilocybin, lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-N-methamphetamine (MDMA). The study provided an overview of PAT as currently provided in Switzerland under the regulatory framework of the Federal Office of Public Health (FOPH)....
Medicinska istrazivanja
2026
Stefan Jerotić, Olga Čolović, Nađa Marić
Psychedelic-assisted psychotherapy (PAP) is emerging as a novel intervention for major psychiatric disorders, most notably major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). While psychotherapy is widely regarded as a core element of PAP its precise role remains poorly defined. This narrative review traces the development of PAP within contemporary Western psychiatry,...
Palliative & Supportive Care
2026
Stephen P. Lewis
1 citation
OBJECTIVES: People with serious illnesses often experience spiritual and emotional pain, manifesting in conditions such as depression, anxiety, and demoralization. Emerging research in psychedelic-assisted therapy has shown efficacy in treating these conditions. Despite evidence that psychedelics frequently occasion mystical/spiritual experiences in participants, there has been little research...
Annals of medicine and surgery (2012)
2026
Sana Rasheed, Rida Arif, Ahmed Asad Raza et al.
1 citation
Psilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), particularly in cases where traditional treatments prove ineffective. The study aims to evaluate psilocybin's therapeutic potential by examining its efficacy, safety, and mechanisms of action as well as addressing the societal and regulatory...
Journal of Psychoactive Drugs
2026
Philip Kamilar-Britt, Alyssa B. Oliva, Mitch Earleywine
Nicotine dependence remains a leading cause of preventable mortality worldwide. Pharmacotherapy and behavioral interventions offer modest efficacy with limited long-term success. Psilocybin-assisted psychotherapy (PAP) is an emerging approach to nicotine cessation with a growing evidence base. As PAP research expands, understanding how nicotine users' attitudes shape treatment engagement...